Anagrelide: A decade of clinical experience with its use for the treatment of primary thrombocythaemia

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 8, 2004, Pages 1781-1798

  Petrides, Petro E ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anagrelide; Drug metabolism; Hydroxyurea; Leukaemia; Megakaryocyte inhibition; Phosphodiesterase 3; Primary (essential) thrombocythaemia

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALPHA INTERFERON; ANAGRELIDE; BASIC FIBROBLAST GROWTH FACTOR; BUSULFAN; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; HYDROXYUREA; MELPHALAN; PHOSPHODIESTERASE; PHOSPHORUS; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; THROMBOREDUCTIN; TRANSFORMING GROWTH FACTOR BETA; WARFARIN;

ABDOMINAL PAIN; ALLERGIC PNEUMONITIS; ANEMIA; ANKLE EDEMA; ATRIOVENTRICULAR BLOCK; BLEEDING; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; ERYTHROMELALGIA; FLATULENCE; FLUID RETENTION; FOOD DRUG INTERACTION; FREQUENCY ANALYSIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE TARGETING; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPOTENSION; LEUKEMIA; LIFE EXPECTANCY; LUNG DISEASE; LUNG EMBOLISM; MEGAKARYOCYTE; MYELOFIBROSIS; NAUSEA; NONHUMAN; ORAL BLEEDING; PARESTHESIA; PORTAL VEIN THROMBOSIS; REVIEW; SIDE EFFECT; SKIN BLEEDING; SKIN MANIFESTATION; SPLEEN INFARCTION; TACHYCARDIA; TERATOGENICITY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; CARCINOGENS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HEART DISEASES; HUMANS; HYDROXYUREA; INTERFERON TYPE I, RECOMBINANT; MUTAGENS; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; QUINAZOLINES; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOEMBOLISM;

EID: 4344605780     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.8.1781     Document Type: Review

References (132)

1. SCHAFER A: Thrombocytosis. N. Engl. J. Med. (2004) 350:1211-1219.
2. Molecular basis of chronic myeloproliferative disorders, Petrides PE, Pahl HL (Eds), Springer Publ. Co., Heidelberg, New York (2004) (In Press).
3. AOP Vienna, Data on File.
4. FLEMING JS, BUYNISKI JP: A new potent inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb. Res. (1979) 15:373-388.
5. TANG SS, FROJMOVIC MM: Inhibition of platelet function by antithrombotic agents which selectively inhibit low kin cyclic 3′,5′-adenosine monophosphate phosphodiesterase. J. Lab. Clin. Med. (1980) 95:241-257.
6. CLARK WF, REID BD, TEVAARWERK GJ: Anagrelide: inhibitor of collagen and immune complex induced platelet aggregation and release. Thromb. Res. (1981) 21:215-219.
7. CLARK WF, TEVAARWERK GJ, MORIARITY TA, REID BD: Inhibitors of immune complex induced human platelet aggregation and release in plasma. Thromb, Res. (1982) 28:681-688.
8. SMITH JB: Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase. Thromb. Res. (1982) 28:477-485.
9. SEILER S, ARNOLD AJ, GROVE RI et al.: Effects of anagrelide on platelet cAMP levels, cAMP dependent protein kinase and thrombin induced Calcium fluxes. J. Pharmacol. Exp. Ther. (1987) 243:767-774.
10. GILLESPIE E: Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity Biochem. Pharmacol. (1988) 37:2866-2868.
11. GROVE RI, EULER CC, STANTON HC: Anagrelide, a potent inhibitor of platelet aggregation inhibits inositol phosphate generation and elevates cAMP. 70th Annual Meeting of the Federation of American Societies for Experimental Biology (1986):Abstract 394.
12. COURTWRIGHT WE, BUCHANON JO, FLEMING JS, TAYLOR R: The effect of multiple oral doses of anagrelide on ADP and collagen-induced platelet aggregation in normal male subjects. Clin. Pharmacol. Ther. (1983):220 (Abstract).
13. COLTON DG, PAIGE JB, FLEMING JS, BUYNISKI JP: Effect of the antithrombotic agent anagrelide (AL) on thrombin-stimulated human platelet arachidonic acid (AA) metabolism. Fed. Amer. Soc. Exp. Biol. (1982):Abstract 7557.
14. BALDUINI CL, BERTOLINO G, NORIS P, ASCARI E: Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica (1992) 77:40-43.
15. HARRISON P: Progress in the assessment of platelet function. Br. J. Haematol. (2000) 111:733-744.
16. DRESCHER CW, CHUCALES AG, GROCOCK AM, LUCCHESI BR: The effects of BL-4162A on the development of coronary artery thrombosis in the conscious rat. Clin. Res. (1979) 27:716A.
17. 111Indium labelled autologous platelet survival during aggregation inhibition by anagrelide in normal volunteers. Clin. Pharm. Ther. (1983) 33:219.
18. PLAPP F, SINOR L, SCHMITZ R et al.: Effect of anagrelide on platelet counts and size. Clin. Pharmacol. Ther. (1983) 33:223 (Abstract C52).
19. TAYLOR R, FLEMING S, ARNOLD J: The effect on platelets of a stable orally active imidazoquinazoline. J. Clin. Pharmacol. (1984) 24:423 (Abstract).
20. ANDES WA, NOVECK RJ, FLEMING JS: Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb. Hemostasis (1984) 52:325-328.
21. HERRON KJ, FLEMING JS, SOLBERG LA: Inhibition of megakaryocyte colonies in vitro by anagrelide. Clin. Res. (1986) 34:459.
22. SOLBERG LA, TEFFERI A, OLES KJ et al.: The effects of anagrelide on human megakaryocytopoiesis. Br. J. Haematol. (1997) 99:174-180.
23. MAZUR EM, ROSMARIN AG, SOHL PA et al.: Analysis of the mechanism of anagrelide induced thrombocytopenia in humans. Blood (1992) 79:1931-1937.
24. BELLUCCI S, LEGRAND C, BOVAL B, DROUET L, CAEN J: Studies on platelet volume, chemistry and function in patients with essentiell thrombocythemia treated with anagrelide. Br. J. Haematol. (1999) 104:886-892.
25. LEV PR, MARTA RF, VASSALLU P, MOLINAS FC: Variation of PDGF, TGF-β and bFGF levels in essential thrombocythemia patients treated with anagrelide. Am. J. Hematol. (2002) 70:85-91.
26. LAGUNA MS, KORNBLIHTT LI, MARTA RF, MOLINAS FC: Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide. Medicina (B Aires) (2000) 60:448-452.
27. TOMER A, STAHL RL, HARKER LA: Anagrelide normalizes platelet count in essential thrombocythemia by decreasing megakaryocyte hypermaturation. Blood (1991) 78(Suppl. 1):145a (Abstract 570).
28. TOMER A: Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood (2002) 99:1602-1609.
29. THIELE J, KVASNICKA HM, SCHMITT-GRÄFF A: Anagrelide induzierte Veränderungen der Megakaryopoiese bei der Therapie thrombozythämischer chronischer myeloproliferativer Erkrankungen. Pathologe (2002) 23:426-432.
30. THIELE J, KVASNICKA HM, FUCHS N, BRUNNBAUER K, VOLKWEIN N, SCHMITT-GRAEFF A: Anagrelide induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica (2003) 88:1130-1138.
31. YOON S-Y, LI C-Y, MESA RA, TEFFERI A: Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol. (1999) 106:682-688.
32. KASTNER PR, FLEMING JS, GILLESPIE E et al.: Inotropic and cardiovascular effects of anagrelide. Proc. Fed. Amer. Soc. Exp. Biol. (1985) 44:716.
33. SILVERSTEIN MN, PETITT RM, SOLBERG LA, FLEMING JS, KNIGHT RC, SCHACTER LP: Anagrelide: new drug for treating thrombocytosis. N. Engl. J. Med. (1988) 318:1292-1294.
34. GAVER RC, DEEB G, PITTMAN KA, SMYTH RD: Disposition of anagrelide, an inhibitor of platelet aggregation. Clin. Pharm. Ther. (1981) 29:381-386.
35. PETRIDES PE, TRAPP O, BEYKIRCH MK: Anagrelide (Agrelin): Pharmakologisches Profil und Klinische Anwendung. Der Onkologe (1997) 3:298-302.
36. LANE WJ, HATTORI K, DIAS S et al.: Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. Exp. Hematol. (2001) 29:1417-1424.
37. ERUSALIMSKI JD, HONG Y, FRANKLIN R: Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)? Exp. Hematol. (2002) 30:625-626.
38. ERUSALIMSKI JD, WANG G, HONG Y: The anagrelide metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603) is a poor inhibitor of in vitro megakaryopoiesis. American Society of Hematology. Blood (2002) (Abstract 4950).
39. MCCARTY JM, MELONE PM, HEISEY C, DESSYPRIS EN: Differences in the species specific activity of anagrelide is mediated through the c-mpl receptor. Blood (2000) 96:743a.
40. RAFIL S, LANE W: In Response. Exp. Hematol. (2002) 30:626-627.
41. KERNS EH: Determination of anagrelide in plasma by capillary gas chromatography-mass spectrometry. J. Chromatography (1987) 416:357-364.
42. PETRIDES PE, BEYKIRCH MK: Efficacy of platelet reduction by anagrelide and safety of this drug in patients with primary thrombocythemia and other CMPDs: an overview of nine prospective non-randomized trials. Hematol. J. (2001) 2:16.
43. ANAGRELIDE STUDY GOUP: Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am. J. Med. (1992) 92:69-76.
44. PETITT RM, SILVERSTEIN MN, PETRONE M: Anagrelide for control of thrombocythemia in polycythemia vera and other myeloproliferative disorders. Sem. Hematol. (1997) 34:51-54.
45. MAZZUCONI MG, DESANCTIS V, CHISTOLINI A et al.: Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Hematologica (1992)77:315-317.
46. PETRIDES PE, BEYKIRCH MK, TRAPP OM: Anagrelide, a novel platelet lowering option in essential thrombocythemia: treatment experience in 48 patients in Germany. Eur. J. Hematol. (1998) 61:71-76.
47. PETRIDES PE, BEYKIRCH MK: Long term follow up of patients with essential thrombocythemia under treatment with anagrelide. American Society of Hematology. Blood (1999) 94:(Suppl. 1):(Abstract 4519).
48. SIEGEL F, PETRIDES PE: Long term analysis of patients with primary thrombocythemia treated with anagrelide for up to 14 years. (In Preparation).
49. TRAPP OM: Anagrelide: ein neuer Wirkstoff zur Behandlung primärer Thrombozythämien. Ludwig-Maximilians-Universität München (1999) (Doctoral Thesis).
50. TRAPP OM, BEYKIRCH MK, PETRIDES PE: Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol. Dis. (1998) 24:9-13.
51. BURKHARD H, ADAM H, WIDMER L et al.: Anagrelide zur Kontrolle der Myeloproliferativen Thrombozytämie: Langzeiterfahrung bei 6 Patienten. Schweiz. Med. Wochenschr. (1998) 128:1808-1812.
52. MILLS AK, TAYLOR KM, WRIGHT SJ et al.: Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythemia. Aust. NZJ. Med. (1999) 29:29-37.
53. LAGUNA MS, KORNBLIHTT LI, MARTA RF et al.: Effectiveness of Anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin. Appl. Thrombosis/Hemostasis (2000) 6:157-161.
54. KNUTSEN H, HYSING J: Anagrelide ved primaer trombocytemi. Tidsskr Nor Lageforen (2001) 212:1478-1482.
55. GISSLINGER H: Use of Anagrelide as monotherapy or in combination with interferon-α or hydroxyurea. Results of the study AOP 02007. German-Austrian Annual Hematology Oncology Meeting, AOP-Symposium, Munich (2002).
56. STEURER M, GASTL G, JEDRCZEJCZAK W et al.: Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile (Submitted).
57. GREEN A, PEARSON T: Position paper on anagrelide. British Society of Hematology, February (2000).
58. SILVERSTEIN MN: Anagrelide in myeloproliferative diseases. In: Polycythemia vera and the myeloproliferative disorders. Wasserman LR, Berk PD, Berlin NI (Eds), Saunders, Philadelphia, USA (1995):329-336.
59. 9/L be used as a diagnostic criterion in essential thrombocythemia? An analysis of the natural course including early stages. Br. J. Haematol. (1998) 100:15-23.
60. 9/L. Haematologica (2000) 85:492-495.
61. REGEV A, STARK P, BLICKSTEIN D et al.: Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am. J. Hematol. (1997) 56:168-172.
62. PETRIDES PE: Pathogenesis of the complications of cMPDs: identification of risk factors. German-Austrian Annual Hematology Oncology Meeting, AOP-Symposium, Munich, Germany (2002).
63. NIMER SD: Essential thrombocythemia: another 'heterogeneous disease' better understood? Blood (1999) 93:415-416.
64. RUIZ-ARGUELLES GJ, RUIZ-DELGADO GJ, RUIZ-REYES G, CHERNOFF SG: Anagrelide induced relapse of a hydroxyurea induced leg ulcer in a patient with primary thrombocythemia, Mayo Clinic Proc. (1998) 73:1125.
65. WIRTH K, SCHOEPF E, MERTELSMANN R et al.: Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count. Br. J. Haematol. (1998) 138:533-535.
66. JAMES CW. Anagrelide induced cardiomyopathy. Pharmacotherapy (2000) 20:1224-1227.
67. BRAESTER A, LAVER B: Anagrelide-induced erectile dysfunction. Ann. Pharmacother. (2002) 36:1291.
68. RHAGAWAN M, MAZER MA, BRINK DJ: Severe hypersensivity pneumonitis associated with anagrelide. Ann. Pharmacother. (2003) 37:1228-1231.
69. SWORDS R, FAY M, O'DONNELL R, MURPHY PT: Anagrelide induced visual hallucinations in a patient with essential thrombocythemia. Eur. J. Haematol. (2004) (In Press).
70. PETRONE ME, WILSON J, PETITT RM, SILVERSTEIN MN: Anagrelide for treatment of thrombocythemia. Br. J. Haematol. (1996) 93(Suppl. 2):237.
71. SILVERSTEIN MN, PETRONE ME, PETITT RM, DEMENT MP, VUKOVICH RA: The safety profile of anagrelide for treatment of thrombocythemia. Blood (1996) 88(Suppl. 1):583a.
72. SILVERSTEIN MN, TEFFERI A: Treatment of essential thrombocythemia with anagrelide. Sem. Hematol. (1999) 36(Suppl. 2):23-25.
73. STOREN EC, TEFFERI A: Long term use of anagrelide in young patients with essential thrombocythemia. Blood (2001) 97:863-866.
74. KORNBLIHTT LI, VASSALLU PS, HELLER P, MOLINAS FC: Treatment of essential thrombocythemia with anagrelide: a ten year experience. Medicina (B Aires) (2002) 62:231-236.
75. BIRGEGARD G, BJORKHOLM M, KUTTI J et al.: Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica (2004) 89:520-527.
76. ROSENBAUM H, BENNETT M, BRAESTER A et al.: Toxicity of treatment with anagrelide for thrombocytosis in myeloproliferative disorders. American Society of Hematology. Blood (2002) (Abstract 3151).
77. FRUCHTMAN SM, PETITT RM, GILBERT HS, FIDDLER G, LYNE A: Anagrelide. Analysis of long term safety and leukemogenic potential in myeloproliferative diseases (MPDs). American Society of Hematology. Blood (2002) (Abstract 256).
78. MCCUNE JS, LILES D, LUINDLEY C: Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations. Pharmacotherapy (1997) 17:822-826.
79. MCCUNE JS, LILES D, LUINDLEY C: Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations-Author's reply. Pharmacotherapy (1998) 18:660-661.
80. PETITT R: Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations - a comment. Pharmacotherapy (1998) 18:659.
81. CORTELAZZO S, MARCHETTI M, ORLANDO E et al.: Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway. Am. J. Hematol. (1998) 57:277-282.
82. TSIMBERIDOU AM, COLBURN DE, WELCH MA et al.: Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother. Pharmacol. (2003) 52:229-234.
83. VOSKARIDOU E, TERPOS E, KOMNINAKA V, EFTYHIADIS E, MANTZOURANI M, LOUKOPOULOS D: Chronic myeloid leukemia with marked thrombocytosis in a patient with thalassemia major: complete haematological remission under the combination of hydroxyurea and anagrelide. Br. J. Haematol. (2002) 116:155-157.
84. YOON JM: Combination therapy for essential thrombocythemia. Blood (2002) American Society of Hematology (Abstract 4923).
85. RANDI ML, PUTTI MC: Essential thrombocythaemia in children: is a treatment needed? Expert Opin. Pharmacother. (2004) 5:1009-1014.
86. CHINTAGUMPALA MM, STEUBER CP, MAHONEY DH et al.: Essential thrombocythemia in a child: management with anagrelide. Am J. Pediatr. Hematol. Oncol. (1991) 13:52-56.
87. CHINTAGUMPALA MM, KENNEY LL, STEUBER CP: Treatment of essential thrombocythemia with anagrelide. J. Pediatr. (1995) 127:495-498.
88. HERMANN J, FUCHS D, SAUERBREY A et al.: Successful treatment of essential thrombocythemia with anagrelide in a child. Med. Ped. Oncol. (1998) 30:367-371.
89. LACKNER H, URBAN C, BEHAMSCHMID C et al.: Treatment of children with anagrelide for thrombocythemia. J. Ped. Hematol./Oncol. (1998) 20:469-473.
90. SCHERER S, FERRARI R, RISTER M: Treatment of essential thrombocythemia in childhood. Pediatr. Hematol. Oncol. (2003) 20:361-365.
91. HONG Y, ERUSALIMSKY JD: Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review. Platelets (2003) 13:381-386.
92. FALANGA A, MARCHETTI M, EVANGELISTA V et al.: Polymorphnuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood (2000) 96:4261-4266.
93. CORTELAZZO S et al.: Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis. N. Engl. J. Med. (1995) 332:1132-1136.
94. FINAZZI G, RUGGERI M, REDEGHIERO F, BARBUI T: Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized trial. Br. J. Haematol. (2000) 116:923-924.
95. RING T: Hydroxyurea in essential thrombocythemia. N. Engl. J. Med. (1995) 333:803.
96. FEINER RH: Hydroxyurea in essential thrombocythemia. N. Engl. J. Med. (1995) 333:803.
97. VAN GENDEREN PJ, MICHIELS JJ: Hydroxyurea in essential thrombocythemia. N. Engl. J. Med. (1995) 333:802-803.
98. BRAVO BLANCO AM, MORAL JL, TEMBRAS S et al.: Hydroxyurea induced skin ulcerations in patients with chronic myeloproliferative disorders. J. Hematother. Stem Cell Res. (2003) 12:461-463.
99. SCHWONZON M, SPANGENBERGER H, SPENGLER M: Hydroxyurea induced pneumonitis. Med. Klin. (2003) 98:394-397.
100. BEST PJM, PETITT RM: Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin. Proc. (1998) 73:961-963.
101. BENNETT M, GRUNWALD AJ: Hydroxyurea and periodicity in myeloproliferative disease. Eur. J. Hematol. (2001) 66:317-323.
102. BARBUI T, FINAZZI G, RUGGERI M, RODEGHIERO F: Secondary leukemia following hydroxyurea in patients with essential thrombocythemia: long term results of a randomized clinical trial. American Society of Hematology. Blood (1998) Suppl. 1:(Abstract 2016).
103. FURGERSON JL, VUKELJA SJ, BAKER WJ, O'ROURKE TJ: Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am. J. Hematol. (1996) 51:137-140.
104. NAND S, STOCK W, GODWIN J, FISHER SG: Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am. J. Hematol. (1996) 52:42-46.
105. NIELSEN I, HASSELBALCH HC: Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am. J. Hematol. (2003) 74:26-31.
106. FINAZZI G, RUGGERI M, RODEGHIERO F, BARBUI T: Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood (2003) 101:3749.
107. WEINFELD A, SWOLIN B, WESTIN J: Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders. Eur. J. Haematol, (1994) 52:134-139.
108. STERKERS Y, PREUDHOMME C, LAI J-L et al.: Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood (1998) 91:616-622.
109. QUAGLINIO D, DILEONARDO, STATI M: Leukemic transformation in a case of thrombocythaemia. Case report and review of the literature. Acta Haematol. (2001) 106:122-125.
110. SIRONI M, BERTOLA G, LODATO A et al.: Transition of essential thrombocythemia to megakaryoblastic leukaemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea. Acta Haematol. (2003) 109:161-162.
111. WAHLIN A, GOLOVLEVA I: Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Ph-negative essential thrombocythemia. Eur. J. Haematol. (2003) 70:240-241.
112. RADIN Al, KIM HK, GRANT BW et al.: Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487). Cancer (2003) 98:100-109.
113. ALVARADO Y, CORTES J, VERSTOVSEK S et al.:. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother. Pharmacol. (2003) 51:81-86.
114. GOLUB R, ADAMS J, DAVE S, BENNETT CL: Cost effectiveness considerations in the treatment of essential thrombocythemia. Semin. Oncol. (2002) 29:(Suppl. 10):28-32.
115. BENNETT CL, WEINBERG PO, GOLUB RM: Cost-effectiveness model of a Phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? Semin. Hematol. (1999) 36:(Suppl. 2):26-29.
116. GILBERT H: Clinical status of anagrelide: a selective agent for the control of thrombocythemia in myeloproliferative disorders. Cancer Invest. (1991) 9:343-344.
117. PETRIDES PE: Anagrelid: neues Therapeutikum bei Primärer Thrombozytose. Arzneimitteltherapie (1993) 11:71-73.
118. BEYKIRCH MK, TRAPP O, PETRIDES PE: Primäre Thrombozythämie. Diagnose und Therapie. Arzneimitteltherapie (1997) 15:309-311.
119. PETITT RM, PETRIDES PE: Platelet reductive treatment with anagrelide in thrombocythemic states: experiences in various centers and future directions. European working group on myeloproliferative disorders. Second Congress of the European Society of Hematology, Paris, France, May (1996).
120. SPENCER CM, BRODGEN, RN: Anagrelide. Drugs (1994) 47:809-822.
121. TEFFERI A, SILVERSTEIN MN, PETITT RM, MESA RA, SOLBERG LA: Anagrelide as a new platelet lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Sem. Thrombosis Hemostasis (1997) 23:379-383.
122. PETRIDES PE: Agrelin® (Anagrelide) is an efficacious platelet reducing drug in patients with primary thrombocythemia. Blood(1994) 84:S635a.
123. PETRIDES PE, TRAPP OM, BEYKIRCH MK: Anagrelide, a novel specific inhibitory agent for patients with primary thrombocythemia. Onkologie (1995) 17(Suppl. 2):111.
124. PETRIDES PE: Treatment of essential thrombocythemia with Agrelin®: the German experience. Br. J. Haematol. (1996) 93(Suppl. 2):237 (Abstract 892).
125. PETRIDES PE, TRAPP OM, BEYKIRCH MK: Agrelin® (Anagrelide), a novel drug for the treatment for the treatment of primary thrombocytoses (ET, PV and CML): experience on 40 patients in Germany. Ann. Hematol. (1996) 73(Suppl. II):A97.
126. PETRIDES PE, TRAPP OM, BEYKIRCH MK: Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood (1997) 90(Suppl. 1) American Society of Hematology (Abstract 4009).
127. PETRIDES PE: Treatment of essential thrombocythemia with anagrelide in 60 patients from Germany. J. Clin. Oncol. (1997) 16:35a.
128. OERTEL MD: Anagrelide, a selective thrombocytopenic agent. Am. J. Health System Pharm. (1998) 55:1979-1986.
129. BROOKS WG, STANLEY DD, GOODE J: Role of anagrelide in the treatment of thrombocytosis. Ann. Pharmacother. (1999) 33:1116-1121.
130. PESCATORE SL, SINDLEY C: Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin. Pharmacother. (2000) 1:537-546.
131. ANDERSSON BS: Essential thrombocythemia: diagnosis and treatment with special emphasis on the use of anagrelide. Hematology (2002) 7:173-177.
132. ADAMSON JW: Wither the platelet? N. Engl. J. Med. (1988) 318:1331-1332.